Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 15CNS 3NET 1Genitourinary 1Dermatologic 1

Conditions

Neuroendocrine Tumors 15Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Carcinoid Tumor 2Serotonin Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Disease 1Digestive System Neuroendocrine Tumor G1 1Colorectal Neoplasms 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Adenoma 1Acromegaly 1

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pituitary Neoplasms × NET × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡